-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back at 2021, the innovative drug industry is booming due to multiple resonances such as policies, talents, and capital.
Under this background, innovative drug companies are enthusiastic about going public
.
According to statistics, in 2021, a total of 19 innovative drug companies will be listed on A shares and Hong Kong shares
.
Although 8 of them broke on the first day of listing, such as BeiGene, Dizhe Pharmaceuticals, Chengda Biology, Nanmo Biology and so on
.
Although the listing standards for pharmaceutical companies are tightening, the industry expects that in 2022, the popularity of innovative pharmaceutical companies is expected to continue, and the number of innovative pharmaceutical companies landing in the capital market this year is expected to break through again
.
As of January 6, 2022, judging from the current status of innovative drug IPO applications on the main board of the Hong Kong Stock Exchange, there are 8 innovative drug companies whose IPO applications are being processed, including Sidi Pharmaceuticals, Ruike Bio, Tianguangshi, Ai U.
S.
Vaccines, Biositu, Arnold Pharmaceuticals, Yaojie Ankang, and Lepu Biopharmaceuticals mainly focus on tumor, autoimmunity, vaccines and other fields
.
Another 4 shares are currently no progress
.
On the SSE STAR Market, Asieris Pharmaceuticals and Maiwei Bio have been issued, Haichuang Pharmaceutical, Shouyao Holding, and Sailun Bio have been submitted to the China Securities Regulatory Commission, and Xintong Pharmaceutical, Baili Tianheng, and Mengke Pharmaceutical have been inquired.
, In addition, 1 innovative drug company's IPO application status has been replied, and the voting has been suspended
.
Among them, Asieris Pharmaceuticals was listed on the Science and Technology Innovation Board in January and July 2022.
It is an innovative drug company dedicated to providing patients with integrated solutions for diagnosis and treatment and deeply cultivating the field of genitourinary tumor treatment
.
At present, the company's products have not yet been listed.
It has two core products under development, APL-1202 and APL-1702.
The company's listing price is 22.
98 yuan per share, and it plans to raise 2.
07 billion yuan, mainly for drugs, medical devices and supporting applications.
Cream production projects, new drug research and development projects, marketing network construction projects and supplementary working capital
.
According to the exchange, Maiwei Bio has also announced the results of the online lottery.
There are 52,882 winning numbers, and each winning number can only subscribe for 500 Maiwei Bio A shares
.
In addition, there is also an IPO application for an innovative drug company on the ChiNext Board of the Shenzhen Stock Exchange, namely Hualan Vaccine, which has also been submitted to the China Securities Regulatory Commission. .
It has been more than a year since the stock submitted its prospectus to the GEM of the Shenzhen Stock Exchange, and the IPO process has been bumpy, so it has attracted the attention of the industry
.
It is understood that before the spin-off of Hualan Vaccine, the vaccine sector, as the main business of Hualan Bio, has achieved rapid growth for three consecutive years
.
In addition, in recent years, the gross profit margin of Hualan vaccine's main business has also increased year by year.
From 2018 to 2020 and the first half of 2021, the gross profit margin of Hualan vaccine sales was 84.
19%, 84.
65%, 89.
37% and 91.
21%, respectively
.
However, the company's single product structure, coupled with a high proportion of promotion service costs, has been repeatedly inquired by the Shenzhen Stock Exchange before.
Whether the IPO can go smoothly is worthy of continuous attention
.
From the perspective of the industry, 2021 will be affected by a combination of factors such as the accelerated rhythm of new stock issuance, the lack of popularity in the capital market, and the return of corporate valuations, resulting in frequent IPOs of innovative drug companies.
In the long run, with the advancement of medical reform policies, and Policies force "pseudo-innovation" to be "true innovation".
Local innovative drug companies will pay more attention to R&D investment and continuously improve their R&D capabilities.
Against this background, China's innovative drug development will develop in a positive direction
.
It is expected in the industry that as more and more innovative drug companies enter the late stage of research and development, competition on the track will become more intense, and innovative drug companies that focus on source innovation and differentiated competitiveness are expected to be more recognized by the capital market
.
Under this background, innovative drug companies are enthusiastic about going public
.
According to statistics, in 2021, a total of 19 innovative drug companies will be listed on A shares and Hong Kong shares
.
Although 8 of them broke on the first day of listing, such as BeiGene, Dizhe Pharmaceuticals, Chengda Biology, Nanmo Biology and so on
.
Although the listing standards for pharmaceutical companies are tightening, the industry expects that in 2022, the popularity of innovative pharmaceutical companies is expected to continue, and the number of innovative pharmaceutical companies landing in the capital market this year is expected to break through again
.
As of January 6, 2022, judging from the current status of innovative drug IPO applications on the main board of the Hong Kong Stock Exchange, there are 8 innovative drug companies whose IPO applications are being processed, including Sidi Pharmaceuticals, Ruike Bio, Tianguangshi, Ai U.
S.
Vaccines, Biositu, Arnold Pharmaceuticals, Yaojie Ankang, and Lepu Biopharmaceuticals mainly focus on tumor, autoimmunity, vaccines and other fields
.
Another 4 shares are currently no progress
.
On the SSE STAR Market, Asieris Pharmaceuticals and Maiwei Bio have been issued, Haichuang Pharmaceutical, Shouyao Holding, and Sailun Bio have been submitted to the China Securities Regulatory Commission, and Xintong Pharmaceutical, Baili Tianheng, and Mengke Pharmaceutical have been inquired.
, In addition, 1 innovative drug company's IPO application status has been replied, and the voting has been suspended
.
Among them, Asieris Pharmaceuticals was listed on the Science and Technology Innovation Board in January and July 2022.
It is an innovative drug company dedicated to providing patients with integrated solutions for diagnosis and treatment and deeply cultivating the field of genitourinary tumor treatment
.
At present, the company's products have not yet been listed.
It has two core products under development, APL-1202 and APL-1702.
The company's listing price is 22.
98 yuan per share, and it plans to raise 2.
07 billion yuan, mainly for drugs, medical devices and supporting applications.
Cream production projects, new drug research and development projects, marketing network construction projects and supplementary working capital
.
According to the exchange, Maiwei Bio has also announced the results of the online lottery.
There are 52,882 winning numbers, and each winning number can only subscribe for 500 Maiwei Bio A shares
.
In addition, there is also an IPO application for an innovative drug company on the ChiNext Board of the Shenzhen Stock Exchange, namely Hualan Vaccine, which has also been submitted to the China Securities Regulatory Commission. .
It has been more than a year since the stock submitted its prospectus to the GEM of the Shenzhen Stock Exchange, and the IPO process has been bumpy, so it has attracted the attention of the industry
.
It is understood that before the spin-off of Hualan Vaccine, the vaccine sector, as the main business of Hualan Bio, has achieved rapid growth for three consecutive years
.
In addition, in recent years, the gross profit margin of Hualan vaccine's main business has also increased year by year.
From 2018 to 2020 and the first half of 2021, the gross profit margin of Hualan vaccine sales was 84.
19%, 84.
65%, 89.
37% and 91.
21%, respectively
.
However, the company's single product structure, coupled with a high proportion of promotion service costs, has been repeatedly inquired by the Shenzhen Stock Exchange before.
Whether the IPO can go smoothly is worthy of continuous attention
.
From the perspective of the industry, 2021 will be affected by a combination of factors such as the accelerated rhythm of new stock issuance, the lack of popularity in the capital market, and the return of corporate valuations, resulting in frequent IPOs of innovative drug companies.
In the long run, with the advancement of medical reform policies, and Policies force "pseudo-innovation" to be "true innovation".
Local innovative drug companies will pay more attention to R&D investment and continuously improve their R&D capabilities.
Against this background, China's innovative drug development will develop in a positive direction
.
It is expected in the industry that as more and more innovative drug companies enter the late stage of research and development, competition on the track will become more intense, and innovative drug companies that focus on source innovation and differentiated competitiveness are expected to be more recognized by the capital market
.
